Company representatives have eluded to P2 results leading to typically a good high transaction period.
The CEO said, paraphrased, "sooner than later" is the preference likely referring to P2. Transaction has been stated by the CEO repeatedly, even before he was CEO.
Both the CEO and Dr Peter Smith have referenced more aggressive licensing deals off the back of P1/during P2 in Asia.
In the AGM and updated clinical plan you will find lots of hints and flat out goals of the company directly from the horses mouths, and they are amazing 1 hour encapsulations of the broader RAC story.
Cardioprotection thread, page-724
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |